A szorongásos betegségek kezelésének farmakogenetikai aspektusai a szerotonerg rendszeren túl: Rövid összefoglalás

Translated title of the contribution: Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: A brief review

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Anxiety disorders (ADs) are among the most frequent psychiatric disorders. In addition, key features of ADs include that they are among the earliest mental disorders to manifest and that their first specific treatment frequently occurs several years after the onset of symptoms. Although the heritability of anxiety disorders is well known, the genetic determination of response to different modalities (psycho- or pharmacotherapy) used in treatment of patients with ADs is lesser investigated. Several studies focused on the role of serotonergic genes in the etiopathology and pharmacotherapy of anxiety disorders, however, less attention was paid to variants of other genes. In this review we focus on the cytochrome P 450, BDNF, COMT, MAOA, EAA-3 transporter, dopamine transporter and dopamine receptor gene polymorphisms and their effects with respect to the pharmacogenetics of anxiety disorders. We discuss the current knowledge on pharmacogenetic/therapygenetic aspects of anxiety disorders beyond the serotonergic system.

Original languageHungarian
Pages (from-to)221-229
Number of pages9
JournalNeuropsychopharmacologia Hungarica
Volume14
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Anxiety Disorders
Pharmacogenetics
Therapeutics
Genes
Drug Therapy
Dopamine Plasma Membrane Transport Proteins
Brain-Derived Neurotrophic Factor
Dopamine Receptors
Mental Disorders
Psychotherapy
Cytochrome P-450 Enzyme System
Psychiatry

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

@article{7ceb7a1955be4d23a0daa3dfd8d87d89,
title = "A szorong{\'a}sos betegs{\'e}gek kezel{\'e}s{\'e}nek farmakogenetikai aspektusai a szerotonerg rendszeren t{\'u}l: R{\"o}vid {\"o}sszefoglal{\'a}s",
abstract = "Anxiety disorders (ADs) are among the most frequent psychiatric disorders. In addition, key features of ADs include that they are among the earliest mental disorders to manifest and that their first specific treatment frequently occurs several years after the onset of symptoms. Although the heritability of anxiety disorders is well known, the genetic determination of response to different modalities (psycho- or pharmacotherapy) used in treatment of patients with ADs is lesser investigated. Several studies focused on the role of serotonergic genes in the etiopathology and pharmacotherapy of anxiety disorders, however, less attention was paid to variants of other genes. In this review we focus on the cytochrome P 450, BDNF, COMT, MAOA, EAA-3 transporter, dopamine transporter and dopamine receptor gene polymorphisms and their effects with respect to the pharmacogenetics of anxiety disorders. We discuss the current knowledge on pharmacogenetic/therapygenetic aspects of anxiety disorders beyond the serotonergic system.",
keywords = "Anxiety disorders, Anxiolytics, Benzodiazepines, Panic disorder, Pharmacogenetics, PTSD, Selective serotonin reuptake inhibitors, Treatment response",
author = "G. Faludi and X. Gonda and G. Bagdy and P. D{\"o}me",
year = "2012",
doi = "10.5706/nph201212002",
language = "Hungarian",
volume = "14",
pages = "221--229",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "4",

}

TY - JOUR

T1 - A szorongásos betegségek kezelésének farmakogenetikai aspektusai a szerotonerg rendszeren túl

T2 - Rövid összefoglalás

AU - Faludi, G.

AU - Gonda, X.

AU - Bagdy, G.

AU - Döme, P.

PY - 2012

Y1 - 2012

N2 - Anxiety disorders (ADs) are among the most frequent psychiatric disorders. In addition, key features of ADs include that they are among the earliest mental disorders to manifest and that their first specific treatment frequently occurs several years after the onset of symptoms. Although the heritability of anxiety disorders is well known, the genetic determination of response to different modalities (psycho- or pharmacotherapy) used in treatment of patients with ADs is lesser investigated. Several studies focused on the role of serotonergic genes in the etiopathology and pharmacotherapy of anxiety disorders, however, less attention was paid to variants of other genes. In this review we focus on the cytochrome P 450, BDNF, COMT, MAOA, EAA-3 transporter, dopamine transporter and dopamine receptor gene polymorphisms and their effects with respect to the pharmacogenetics of anxiety disorders. We discuss the current knowledge on pharmacogenetic/therapygenetic aspects of anxiety disorders beyond the serotonergic system.

AB - Anxiety disorders (ADs) are among the most frequent psychiatric disorders. In addition, key features of ADs include that they are among the earliest mental disorders to manifest and that their first specific treatment frequently occurs several years after the onset of symptoms. Although the heritability of anxiety disorders is well known, the genetic determination of response to different modalities (psycho- or pharmacotherapy) used in treatment of patients with ADs is lesser investigated. Several studies focused on the role of serotonergic genes in the etiopathology and pharmacotherapy of anxiety disorders, however, less attention was paid to variants of other genes. In this review we focus on the cytochrome P 450, BDNF, COMT, MAOA, EAA-3 transporter, dopamine transporter and dopamine receptor gene polymorphisms and their effects with respect to the pharmacogenetics of anxiety disorders. We discuss the current knowledge on pharmacogenetic/therapygenetic aspects of anxiety disorders beyond the serotonergic system.

KW - Anxiety disorders

KW - Anxiolytics

KW - Benzodiazepines

KW - Panic disorder

KW - Pharmacogenetics

KW - PTSD

KW - Selective serotonin reuptake inhibitors

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84874064589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874064589&partnerID=8YFLogxK

U2 - 10.5706/nph201212002

DO - 10.5706/nph201212002

M3 - Article

C2 - 23269208

AN - SCOPUS:84874064589

VL - 14

SP - 221

EP - 229

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 4

ER -